Advertisement - see our Ad Policy
Advertisement - see our Ad Policy

Shockwave Therapy for Peyronie’s Disease


Peyronie’s Disease (PD) is a connective tissue disorder involving the growth of fibrous plaques, or scar tissue, in the soft tissue of the penis. It can cause curved, painful erections, difficulty ejaculating, and difficulty urinating. It may affect up to 5% of adult males in the United States.

Treatment options are limited. Several drugs have been shown to be effective; for cases that do not respond to drug therapies, surgical intervention may be possible.

Low-Intensity Extracorporeal Shockwave Therapy (LI-ESWT) – commonly called shockwave therapy – offers a non-invasive alternative treatment option. It has shown promising results in treating PD1 2 3 4 5 6 7 8, as well as erectile dysfunction. The therapy works by breaking down plaque and scar tissue, and by encouraging the growth of healthy new tissue and blood vessels (angiogenesis).

Independent clinical studies have concluded that:

  • Extracorporeal shockwave therapy may be beneficial in the management of Peyronie’s disease for refractory penile pain and plaque size reduction. [1]
  • Our results support SWT as an effective and safe first-line treatment for Peyronie’s disease. [2]
  • LiESWT appears to be safe, has moderate efficacy and is associated with high patient satisfaction rate in the short term. [3]
  • ESWT could be considered a safe and efficient minimally invasive option for the management of the patients suffering from PD. [4]
  • ESWT offers a safe, minimally invasive, OPD based option to the management of the patients of PD in the stable phase of the disease. Patients who do not respond to the conservative line of management can be really benefited by ESWT. [5]
  • Low-intensity extracorporeal shockwave therapy has a certain effect on Peyronie’s disease by relieving plague-induced pain and improving the patient’s penile erection and quality of life. [6]
  • In patients with PD, ESWT leads to pain resolution and ameliorates both EF and QoL. [7]
  • ESWT is an effective complement to vacuum pump therapy[8]

Getting Shockwave Treatments

Get the Phoenix for Erectile Dysfunction
Advertisement - see our Ad Policy

Shockwave therapy is generally administered in a clinical setting using commercial medical devices. It requires a series of treatments – generally over 6-12 weeks – using a medical device that administers sonic “shockwaves” to the penis. Most clinics focus on treating erectile dysfunction. When selecting a clinic, it’s important to find a place that has experience and protocols for treating Peyronie’s Disease.

In 2020, a home treatment device called the Phoenix became available; it has been engineered to provide the same energy signature as clinical equipment.

Dr. Paul Thompson, Chief Medical Office of Launch Medical and owner of The Thompson Clinic, says:

“I have been using this treatment for 4-5 yrs with great results.”

“I typically treat the whole penis but save one pass specifically for the plague. I repeat the procedure no more than twice weekly and have used both PRP and exosomes for injection into the plague. Typically 6-12 treatments are adequate.”

“As a urologist who has tried all available treatment options and find this to be the most successful one with the others resulting in poor response or worsening of the the problem.”


  1. Krieger, John A; Rizk, Paul J; Kohn, Taylor P. “Shockwave Therapy in the Treatment of Peyronie’s Disease.” Sexual Medicine Reviews. Jul 2019. 7(3):499-507.
  2. Skolarikos, A; Alargof, E; Rigas, A; Deliveliotis, Ch ; Konstantinidis, E. “Shockwave therapy as first-line treatment for Peyronie’s disease: a prospective study.” Journal of Endourology. Jan-Feb 2005; 19(1):11-4.
  3. Chung, Eric. “Peyronie’s disease and low intensity shock wave therapy: Clinical outcomes and patient satisfaction rate in an open-label single arm prospective study in Australian men.” Korean Journal of Urology. Nov 2015.
  4. Di Mauro, Marina; Russo, Giorgio Ivan; et al. “Extracorporeal Shock Wave Therapy in Peyronie’s Disease: Clinical Efficacy and Safety from a Single-Arm Observational Study.” The World Journal of Men’s Health. Mar 2019.
  5. Shimpi, Rajendra Kashinath; Jain, Ravi Jineshkumar. “Role of extracorporeal shock wave therapy in management of Peyronie’s disease: A preliminary report.” Urology Annals. Oct-Dec 2016.
  6. Li, Peng-Cheng; Chen, Xin ; Zhu, Xiao-Bo; Shi, Tao; Song, Fei; Huang, Hua-Wei; Zhang, Xiang-Sheng. “Low-intensity extracorporeal shockwave therapy for Peyronie’s disease: A preliminary study of 32 cases.” Zhonghua Nan Ke Xue (National Journal of Andrology). 2018 Apr;24(4):340-344. <>
  7. Palmieri, Alessandro ; Imbimbo, Ciro; Longo, Nicola; Fusco, Ferdinando; Verze, Paolo; Mangiapia, Francesco; Creta, Massimiliano; Mirone, Vincenzo. “A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie’s disease.” European Urology. Aug 2009;56(2):363-9.
  8. Mortensen, Jonas; Skov-Jeppesen, Sune Møller; Ladegaard, Peter Bill Juul; Lund, Lars. “A Randomized, Single-Blinded Clinical Trial Evaluating the Effect of Extracorporeal Shockwave Treatment (ESWT) as Add-On Therapy to Vacuum Erectile Device on Peyronie’s Disease.” Research and Reports in Urology. September 2021; 13: 715–722.

Comments are closed.